AI could also have a transformative effect on clinical decision-making through the utilisation of the huge levels of genomic, biomarker, phenotype, behavioural, biographical and clinical data that is generated across the health system. Bayer and Merck & Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form of pulmonary hypertension. The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and efficiently. The CTEPH Pattern Recognition Artificial Intelligence obtained FDA Breakthrough Device Designation in December 2018.
Aug-11-2020, 04:10:41 GMT